Atopic Dermatitis

ASLAN Pharmaceuticals initiates Phase 2b study of eblasakimab for atopic dermatitis

By Marjorie V. Stimson

Newswires MT 2022

All news about ASLAN PHARMACEUTICALS LIMITED
Sales 2021 –
–
–
Net income 2021 -847M
-30.6M
-30.6M
Net debt 2021 –
–
–
PER 2021 ratio -2.42x
2021 performance –
Capitalization 1,771 million
64.1M
64.0 million
capi. / Sales 2021 –
capi. / Sales 2022 –
# of employees 18
Floating 41.2%

Chart ASLAN PHARMACEUTICALS LIMITED
Duration :

Period :

ASLAN Pharmaceuticals Limited Technical Analysis Chart | MarketScreener

Technical Analysis Trends ASLAN PHARMACEUTICALS LIMITED

Short term Middle term Long term
Tendencies Bearish Bearish Bearish

Evolution of the income statement

To sell

To buy
Medium consensus SURPASS
Number of analysts 4
Last closing price

$0.92

Average target price

$8.00

Average Spread / Target 769%

Related posts:

  1. Botanix (ASX: BOT) share price jumped 20% today
  2. Review reveals several treatment options for AD, more to come
  3. Track Effectiveness in Asthma Management
  4. Rinvoq shows promise as a maintenance drug for ulcerative colitis – PharmaLive
Marjorie V. Stimson
You might also like More from author

Comments are closed.